EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte Studie

Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma

Alexander C J van Akkooi, Christian Blank, Alexander M M Eggermont

European Journal of Cancer · 2023

DOI: 10.1016/j.ejca.2023.01.004 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Alexander C J van Akkooi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma Institute Australia, Sydney, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, Australia; Royal Prince Alfred Hospita…. Hauptthemen laut MEDLINE: Nivolumab, Melanoma. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabMelanomaHumansIpilimumabNeoadjuvant TherapyStandard of CareNeoplasm StagingChemotherapy, AdjuvantAdjuvants, ImmunologicImmunotherapyCutaneous Malignant Melanoma

Stichwörter der Autor:innen

AdjuvantImmunotherapyLymph node metastasisMacroscopic stage IIIMelanomaNeo-adjuvant immunotherapy

Substanzen

IpilimumabNivolumabAdjuvants, Immunologic

Autor:innen und Institutionen

  • Melanoma Institute Australia, Sydney, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, Australia; Royal Prince Alfred Hospital, Sydney, Australia. Electronic address: alexander.vanakkooi@melanoma…
  • Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Leiden University Medical Center, Faculty of Medicine, Leiden, the Netherlands.
  • University Medical Center Utrecht & Princess Maxima Center, Utrecht, the Netherlands; Comprehensive Cancer Center München, Technical University München & Ludwig Maximiliaan University, München, Germany.

Zitieren

APA

van Akkooi, A. C. J., Blank, C., & Eggermont, A. M. M. (2023). Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.01.004

Vancouver

van Akkooi ACJ, Blank C, Eggermont AMM. Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma. European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.01.004

BibTeX
@article{vanAkkooi2023,
  author = {van Akkooi, Alexander C J and Blank, Christian and Eggermont, Alexander M M},
  title = {Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma},
  journal = {European Journal of Cancer},
  year = {2023},
  doi = {10.1016/j.ejca.2023.01.004}
}
Kostenlos starten →